Muzolimine

Summary

Muzolimine (CHEMBL1697760) is an approved small molecule (ATC C03CD01); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03CD01
• Indications: 1 condition
• Chemistry: 272.13 Da · C11H11Cl2N3O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1697760
Name	Muzolimine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	41386
ATC	C03CD01
Molecular formula	C11H11Cl2N3O
Molecular weight	272.13
InChIKey	RLWRMIYXDPXIEX-UHFFFAOYSA-N

SMILES: CC(C1=CC(=C(C=C1)Cl)Cl)N2C(=O)CC(=N2)N

IUPAC name: 5-amino-2-[1-(3,4-dichlorophenyl)ethyl]-4H-pyrazol-3-one

Also known as: BAY G 2821, BAY-G 2821, BAY-G-2821, Edrul, Muzolimina, Muzolimine, MUZOLIMINE, muzolimine

Patent coverage: 981 distinct patent families (3,272 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,271 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).